Implications of a Circulating Vaccine-Derived Poliovirus in Nigeria
Reversion of live attenuated oral poliovirus vaccine strains to a virulent phenotype is a rare but significant occurrence. In Nigeria, at least one vaccine-derived clone of type 2 poliovirus developed virulence, leading to ongoing transmission networks and many cases of paralysis. In this report, th...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2010-06, Vol.362 (25), p.2360-2369 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2369 |
|---|---|
| container_issue | 25 |
| container_start_page | 2360 |
| container_title | The New England journal of medicine |
| container_volume | 362 |
| creator | Jenkins, Helen E Aylward, R. Bruce Gasasira, Alex Donnelly, Christl A Mwanza, Michael Corander, Jukka Garnier, Sandra Chauvin, Claire Abanida, Emmanuel Pate, Muhammad Ali Adu, Festus Baba, Marycelin Grassly, Nicholas C |
| description | Reversion of live attenuated oral poliovirus vaccine strains to a virulent phenotype is a rare but significant occurrence. In Nigeria, at least one vaccine-derived clone of type 2 poliovirus developed virulence, leading to ongoing transmission networks and many cases of paralysis. In this report, the characteristics of polio-associated disease and attack rates for this vaccine-derived clone are compared with circulating wild-type polioviruses 1 and 3. Increased vaccination efforts have significantly contributed to the control of all three serotypes. Implications for the global effort to eradicate polio are considered.
In Nigeria, at least one vaccine-derived clone of type 2 poliovirus developed virulence, leading to ongoing transmission networks and many cases of paralysis. In this report, the characteristics of polio-associated disease and attack rates for this vaccine-derived clone are compared with circulating wild-type polioviruses 1 and 3.
Since 1988, when the World Health Assembly resolved to eradicate poliovirus, the annual incidence of paralytic poliomyelitis has fallen by more than 99%. However, the annual number of cases reported for the years 2003 through mid-2009 has remained relatively constant, and continued transmission in endemic countries, especially Nigeria, led to a resurgence of re-infected countries across Africa from 2008 through 2009.
1
,
2
The emergence of a serotype 2 circulating vaccine-derived poliovirus (cVDPV) in Nigeria has complicated the epidemiology of polio as well as vaccine selection and scheduling for supplementary immunization activities.
3
A cVDPV is defined by the appearance of two . . . |
| doi_str_mv | 10.1056/NEJMoa0910074 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733301644</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>733301644</sourcerecordid><originalsourceid>FETCH-LOGICAL-c484t-d4eaea71b8672a37d1ca5beb55d3ee76ad1118e87c0f29bbe9558052d8ed83b73</originalsourceid><addsrcrecordid>eNp10E1r20AQBuClpNSO22OvQQRKTkpmv7SrY3C-HBK3h7ZXsVqNzBpJ6-xagf77brDTNIHMZWB4mBleQr5SOKUgi7Pl5e29N1BSACU-kCmVnOdCQHFApgBM50KVfEIOY1xDKirKT2TCQCpeMjEl80W_6Zw1W-eHmPk2M9ncBTt2aTKsst_GWjdgfoHBPWKT_fCd848ujDFzQ7Z0qzQ3n8nH1nQRv-z7jPy6uvw5v8nvvl8v5ud3uRVabPNGoEGjaK0LxQxXDbVG1lhL2XBEVZiGUqpRKwstK-saSyk1SNZobDSvFZ-Rk93eTfAPI8Zt1btosevMgH6MleKcAy2ESPL4jVz7MQzpuUoySLEpDQnlO2SDjzFgW22C6034U1GonrKtXmWb_NF-6Vj32PzTz2Em8G0PTLSma4MZrIsvjpVAGf_P9X2sBlz37xz8C95qi7c</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>520056780</pqid></control><display><type>article</type><title>Implications of a Circulating Vaccine-Derived Poliovirus in Nigeria</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>New England Journal of Medicine</source><creator>Jenkins, Helen E ; Aylward, R. Bruce ; Gasasira, Alex ; Donnelly, Christl A ; Mwanza, Michael ; Corander, Jukka ; Garnier, Sandra ; Chauvin, Claire ; Abanida, Emmanuel ; Pate, Muhammad Ali ; Adu, Festus ; Baba, Marycelin ; Grassly, Nicholas C</creator><creatorcontrib>Jenkins, Helen E ; Aylward, R. Bruce ; Gasasira, Alex ; Donnelly, Christl A ; Mwanza, Michael ; Corander, Jukka ; Garnier, Sandra ; Chauvin, Claire ; Abanida, Emmanuel ; Pate, Muhammad Ali ; Adu, Festus ; Baba, Marycelin ; Grassly, Nicholas C</creatorcontrib><description>Reversion of live attenuated oral poliovirus vaccine strains to a virulent phenotype is a rare but significant occurrence. In Nigeria, at least one vaccine-derived clone of type 2 poliovirus developed virulence, leading to ongoing transmission networks and many cases of paralysis. In this report, the characteristics of polio-associated disease and attack rates for this vaccine-derived clone are compared with circulating wild-type polioviruses 1 and 3. Increased vaccination efforts have significantly contributed to the control of all three serotypes. Implications for the global effort to eradicate polio are considered.
In Nigeria, at least one vaccine-derived clone of type 2 poliovirus developed virulence, leading to ongoing transmission networks and many cases of paralysis. In this report, the characteristics of polio-associated disease and attack rates for this vaccine-derived clone are compared with circulating wild-type polioviruses 1 and 3.
Since 1988, when the World Health Assembly resolved to eradicate poliovirus, the annual incidence of paralytic poliomyelitis has fallen by more than 99%. However, the annual number of cases reported for the years 2003 through mid-2009 has remained relatively constant, and continued transmission in endemic countries, especially Nigeria, led to a resurgence of re-infected countries across Africa from 2008 through 2009.
1
,
2
The emergence of a serotype 2 circulating vaccine-derived poliovirus (cVDPV) in Nigeria has complicated the epidemiology of polio as well as vaccine selection and scheduling for supplementary immunization activities.
3
A cVDPV is defined by the appearance of two . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMoa0910074</identifier><identifier>PMID: 20573924</identifier><identifier>CODEN: NEJMAG</identifier><language>eng</language><publisher>Waltham, MA: Massachusetts Medical Society</publisher><subject>Adolescent ; Biological and medical sciences ; Child ; Child, Preschool ; General aspects ; Humans ; Immunization ; Infant ; Medical sciences ; Nigeria - epidemiology ; Paralysis ; Paraplegia - epidemiology ; Paraplegia - virology ; Poliomyelitis ; Poliomyelitis - epidemiology ; Poliomyelitis - etiology ; Poliomyelitis - prevention & control ; Poliomyelitis - virology ; Poliovirus - immunology ; Poliovirus - pathogenicity ; Poliovirus Vaccine, Oral - administration & dosage ; Poliovirus Vaccine, Oral - adverse effects ; Poliovirus Vaccine, Oral - immunology ; Population Surveillance ; Severity of Illness Index ; Vaccination - adverse effects ; Vaccines</subject><ispartof>The New England journal of medicine, 2010-06, Vol.362 (25), p.2360-2369</ispartof><rights>Copyright © 2010 Massachusetts Medical Society. All rights reserved.</rights><rights>2015 INIST-CNRS</rights><rights>2010 Massachusetts Medical Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c484t-d4eaea71b8672a37d1ca5beb55d3ee76ad1118e87c0f29bbe9558052d8ed83b73</citedby><cites>FETCH-LOGICAL-c484t-d4eaea71b8672a37d1ca5beb55d3ee76ad1118e87c0f29bbe9558052d8ed83b73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMoa0910074$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.nejm.org/doi/full/10.1056/NEJMoa0910074$$EHTML$$P50$$Gmms$$H</linktohtml><link.rule.ids>314,776,780,2746,2747,26080,27901,27902,52357,54039</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22901234$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20573924$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jenkins, Helen E</creatorcontrib><creatorcontrib>Aylward, R. Bruce</creatorcontrib><creatorcontrib>Gasasira, Alex</creatorcontrib><creatorcontrib>Donnelly, Christl A</creatorcontrib><creatorcontrib>Mwanza, Michael</creatorcontrib><creatorcontrib>Corander, Jukka</creatorcontrib><creatorcontrib>Garnier, Sandra</creatorcontrib><creatorcontrib>Chauvin, Claire</creatorcontrib><creatorcontrib>Abanida, Emmanuel</creatorcontrib><creatorcontrib>Pate, Muhammad Ali</creatorcontrib><creatorcontrib>Adu, Festus</creatorcontrib><creatorcontrib>Baba, Marycelin</creatorcontrib><creatorcontrib>Grassly, Nicholas C</creatorcontrib><title>Implications of a Circulating Vaccine-Derived Poliovirus in Nigeria</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>Reversion of live attenuated oral poliovirus vaccine strains to a virulent phenotype is a rare but significant occurrence. In Nigeria, at least one vaccine-derived clone of type 2 poliovirus developed virulence, leading to ongoing transmission networks and many cases of paralysis. In this report, the characteristics of polio-associated disease and attack rates for this vaccine-derived clone are compared with circulating wild-type polioviruses 1 and 3. Increased vaccination efforts have significantly contributed to the control of all three serotypes. Implications for the global effort to eradicate polio are considered.
In Nigeria, at least one vaccine-derived clone of type 2 poliovirus developed virulence, leading to ongoing transmission networks and many cases of paralysis. In this report, the characteristics of polio-associated disease and attack rates for this vaccine-derived clone are compared with circulating wild-type polioviruses 1 and 3.
Since 1988, when the World Health Assembly resolved to eradicate poliovirus, the annual incidence of paralytic poliomyelitis has fallen by more than 99%. However, the annual number of cases reported for the years 2003 through mid-2009 has remained relatively constant, and continued transmission in endemic countries, especially Nigeria, led to a resurgence of re-infected countries across Africa from 2008 through 2009.
1
,
2
The emergence of a serotype 2 circulating vaccine-derived poliovirus (cVDPV) in Nigeria has complicated the epidemiology of polio as well as vaccine selection and scheduling for supplementary immunization activities.
3
A cVDPV is defined by the appearance of two . . .</description><subject>Adolescent</subject><subject>Biological and medical sciences</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>General aspects</subject><subject>Humans</subject><subject>Immunization</subject><subject>Infant</subject><subject>Medical sciences</subject><subject>Nigeria - epidemiology</subject><subject>Paralysis</subject><subject>Paraplegia - epidemiology</subject><subject>Paraplegia - virology</subject><subject>Poliomyelitis</subject><subject>Poliomyelitis - epidemiology</subject><subject>Poliomyelitis - etiology</subject><subject>Poliomyelitis - prevention & control</subject><subject>Poliomyelitis - virology</subject><subject>Poliovirus - immunology</subject><subject>Poliovirus - pathogenicity</subject><subject>Poliovirus Vaccine, Oral - administration & dosage</subject><subject>Poliovirus Vaccine, Oral - adverse effects</subject><subject>Poliovirus Vaccine, Oral - immunology</subject><subject>Population Surveillance</subject><subject>Severity of Illness Index</subject><subject>Vaccination - adverse effects</subject><subject>Vaccines</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp10E1r20AQBuClpNSO22OvQQRKTkpmv7SrY3C-HBK3h7ZXsVqNzBpJ6-xagf77brDTNIHMZWB4mBleQr5SOKUgi7Pl5e29N1BSACU-kCmVnOdCQHFApgBM50KVfEIOY1xDKirKT2TCQCpeMjEl80W_6Zw1W-eHmPk2M9ncBTt2aTKsst_GWjdgfoHBPWKT_fCd848ujDFzQ7Z0qzQ3n8nH1nQRv-z7jPy6uvw5v8nvvl8v5ud3uRVabPNGoEGjaK0LxQxXDbVG1lhL2XBEVZiGUqpRKwstK-saSyk1SNZobDSvFZ-Rk93eTfAPI8Zt1btosevMgH6MleKcAy2ESPL4jVz7MQzpuUoySLEpDQnlO2SDjzFgW22C6034U1GonrKtXmWb_NF-6Vj32PzTz2Em8G0PTLSma4MZrIsvjpVAGf_P9X2sBlz37xz8C95qi7c</recordid><startdate>20100624</startdate><enddate>20100624</enddate><creator>Jenkins, Helen E</creator><creator>Aylward, R. Bruce</creator><creator>Gasasira, Alex</creator><creator>Donnelly, Christl A</creator><creator>Mwanza, Michael</creator><creator>Corander, Jukka</creator><creator>Garnier, Sandra</creator><creator>Chauvin, Claire</creator><creator>Abanida, Emmanuel</creator><creator>Pate, Muhammad Ali</creator><creator>Adu, Festus</creator><creator>Baba, Marycelin</creator><creator>Grassly, Nicholas C</creator><general>Massachusetts Medical Society</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20100624</creationdate><title>Implications of a Circulating Vaccine-Derived Poliovirus in Nigeria</title><author>Jenkins, Helen E ; Aylward, R. Bruce ; Gasasira, Alex ; Donnelly, Christl A ; Mwanza, Michael ; Corander, Jukka ; Garnier, Sandra ; Chauvin, Claire ; Abanida, Emmanuel ; Pate, Muhammad Ali ; Adu, Festus ; Baba, Marycelin ; Grassly, Nicholas C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c484t-d4eaea71b8672a37d1ca5beb55d3ee76ad1118e87c0f29bbe9558052d8ed83b73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adolescent</topic><topic>Biological and medical sciences</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>General aspects</topic><topic>Humans</topic><topic>Immunization</topic><topic>Infant</topic><topic>Medical sciences</topic><topic>Nigeria - epidemiology</topic><topic>Paralysis</topic><topic>Paraplegia - epidemiology</topic><topic>Paraplegia - virology</topic><topic>Poliomyelitis</topic><topic>Poliomyelitis - epidemiology</topic><topic>Poliomyelitis - etiology</topic><topic>Poliomyelitis - prevention & control</topic><topic>Poliomyelitis - virology</topic><topic>Poliovirus - immunology</topic><topic>Poliovirus - pathogenicity</topic><topic>Poliovirus Vaccine, Oral - administration & dosage</topic><topic>Poliovirus Vaccine, Oral - adverse effects</topic><topic>Poliovirus Vaccine, Oral - immunology</topic><topic>Population Surveillance</topic><topic>Severity of Illness Index</topic><topic>Vaccination - adverse effects</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jenkins, Helen E</creatorcontrib><creatorcontrib>Aylward, R. Bruce</creatorcontrib><creatorcontrib>Gasasira, Alex</creatorcontrib><creatorcontrib>Donnelly, Christl A</creatorcontrib><creatorcontrib>Mwanza, Michael</creatorcontrib><creatorcontrib>Corander, Jukka</creatorcontrib><creatorcontrib>Garnier, Sandra</creatorcontrib><creatorcontrib>Chauvin, Claire</creatorcontrib><creatorcontrib>Abanida, Emmanuel</creatorcontrib><creatorcontrib>Pate, Muhammad Ali</creatorcontrib><creatorcontrib>Adu, Festus</creatorcontrib><creatorcontrib>Baba, Marycelin</creatorcontrib><creatorcontrib>Grassly, Nicholas C</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jenkins, Helen E</au><au>Aylward, R. Bruce</au><au>Gasasira, Alex</au><au>Donnelly, Christl A</au><au>Mwanza, Michael</au><au>Corander, Jukka</au><au>Garnier, Sandra</au><au>Chauvin, Claire</au><au>Abanida, Emmanuel</au><au>Pate, Muhammad Ali</au><au>Adu, Festus</au><au>Baba, Marycelin</au><au>Grassly, Nicholas C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Implications of a Circulating Vaccine-Derived Poliovirus in Nigeria</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2010-06-24</date><risdate>2010</risdate><volume>362</volume><issue>25</issue><spage>2360</spage><epage>2369</epage><pages>2360-2369</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><coden>NEJMAG</coden><abstract>Reversion of live attenuated oral poliovirus vaccine strains to a virulent phenotype is a rare but significant occurrence. In Nigeria, at least one vaccine-derived clone of type 2 poliovirus developed virulence, leading to ongoing transmission networks and many cases of paralysis. In this report, the characteristics of polio-associated disease and attack rates for this vaccine-derived clone are compared with circulating wild-type polioviruses 1 and 3. Increased vaccination efforts have significantly contributed to the control of all three serotypes. Implications for the global effort to eradicate polio are considered.
In Nigeria, at least one vaccine-derived clone of type 2 poliovirus developed virulence, leading to ongoing transmission networks and many cases of paralysis. In this report, the characteristics of polio-associated disease and attack rates for this vaccine-derived clone are compared with circulating wild-type polioviruses 1 and 3.
Since 1988, when the World Health Assembly resolved to eradicate poliovirus, the annual incidence of paralytic poliomyelitis has fallen by more than 99%. However, the annual number of cases reported for the years 2003 through mid-2009 has remained relatively constant, and continued transmission in endemic countries, especially Nigeria, led to a resurgence of re-infected countries across Africa from 2008 through 2009.
1
,
2
The emergence of a serotype 2 circulating vaccine-derived poliovirus (cVDPV) in Nigeria has complicated the epidemiology of polio as well as vaccine selection and scheduling for supplementary immunization activities.
3
A cVDPV is defined by the appearance of two . . .</abstract><cop>Waltham, MA</cop><pub>Massachusetts Medical Society</pub><pmid>20573924</pmid><doi>10.1056/NEJMoa0910074</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2010-06, Vol.362 (25), p.2360-2369 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_733301644 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; New England Journal of Medicine |
| subjects | Adolescent Biological and medical sciences Child Child, Preschool General aspects Humans Immunization Infant Medical sciences Nigeria - epidemiology Paralysis Paraplegia - epidemiology Paraplegia - virology Poliomyelitis Poliomyelitis - epidemiology Poliomyelitis - etiology Poliomyelitis - prevention & control Poliomyelitis - virology Poliovirus - immunology Poliovirus - pathogenicity Poliovirus Vaccine, Oral - administration & dosage Poliovirus Vaccine, Oral - adverse effects Poliovirus Vaccine, Oral - immunology Population Surveillance Severity of Illness Index Vaccination - adverse effects Vaccines |
| title | Implications of a Circulating Vaccine-Derived Poliovirus in Nigeria |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T21%3A00%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Implications%20of%20a%20Circulating%20Vaccine-Derived%20Poliovirus%20in%20Nigeria&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Jenkins,%20Helen%20E&rft.date=2010-06-24&rft.volume=362&rft.issue=25&rft.spage=2360&rft.epage=2369&rft.pages=2360-2369&rft.issn=0028-4793&rft.eissn=1533-4406&rft.coden=NEJMAG&rft_id=info:doi/10.1056/NEJMoa0910074&rft_dat=%3Cproquest_cross%3E733301644%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=520056780&rft_id=info:pmid/20573924&rfr_iscdi=true |